Damora Therapeutics walks into its May 7 earnings report carrying two distinctly uncomfortable facts: a CFO who just stepped down and a short interest that has tripled in six weeks.
The headline from Monday — CFO Lori Firmani's departure effective May 1 — lands three days before a major financial print. That timing sharpens scrutiny on the numbers rather than blunting it. Short sellers clearly noticed: short interest has risen 159% over the past month to reach 91.7% of the free float, with a further 14% jump in the most recent week alone. The ORTEX short score is running at 63, well into elevated territory. Borrow costs have climbed 44% over the same one-month period to roughly 18%, signalling increased demand for shorts even as availability remains moderate at around 115% of short interest — meaning there is still room to build positions, though the cost of doing so has risen materially.
The bull case rests on pipeline potential and fresh analyst conviction. RBC Capital initiated coverage on April 24 with an Outperform rating and a $40 target, following Evercore ISI's initiation in late March at $46. Both actions point to analyst confidence in the science heading into this print. The stock has climbed 3% over the past month to $25.93, and the consensus target of $46 implies roughly 77% upside — a gap that suggests the market is assigning meaningful probability to a negative outcome rather than simply discounting a bullish base case. The bears, meanwhile, are focused on cash burn: the EV/EBITDA multiple is deeply negative and the earnings yield is running at roughly -9.4%, consistent with a pre-revenue biotech spending down its balance sheet.
Past reactions to events have been volatile in both directions. The February print saw the stock drop 15% on the day before recovering more than 18% over the following week. March's event produced a similar same-day drop followed by a larger reversal. That pattern — sharp initial moves that partially reverse — makes the post-print tape particularly hard to read.
The May 7 report therefore tests whether the pipeline narrative can survive CFO-transition scrutiny, and whether management can frame the cash runway convincingly enough to narrow the wide gap between where the stock trades and where analysts think it should be.
See the live data behind this article on ORTEX.
Open DMRA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
